FDA shifts to a single pivotal trial default and issues plausible mechanism guidance to speed individualized therapies for rare genetic diseases.
| less than a minute read
FDA Announces a Single Pivotal Trial as the New Default Standard for All Drug Approvals and Unveils a Plausible Mechanism Framework for Individualized Therapies

/Passle/6880addbd954bf894713d5af/SearchServiceImages/2026-10-14-19-40-55-219-6acfdac75707bcf1c6b313ec.jpg)
/Passle/6880addbd954bf894713d5af/SearchServiceImages/2026-10-14-13-24-34-269-6acf82925707bcf1c6b1ef33.jpg)
/Passle/6880addbd954bf894713d5af/SearchServiceImages/2026-10-14-13-24-59-710-6acf82ab91778041f0064fbd.jpg)
